Search Results
Results found for "Jovanni D Ahmad"
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Career opportunities: Â Senior Scientist, Phage Display | Manager, CMC Management | Translational R&D biotech discovery teams, and decision-makers who need fast, curated, career-relevant intelligence to stay ahead
- Fluorescence Polarization in GPCR Research
Advancing Fluorescence Polarization Assays with Custom Fluorescent Ligands Looking ahead, fluorescence Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-DÃaz R, Majellaro M, Tamhankar AV, Koenekoop L, González
- Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs)...
adenocarcinoma: p = 0.004, mesothelioma: p = 0.039, ovarian serous cystadenocarcinoma: p = 0.048); (d)
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
This Week’s Highlights: G protein-coupled receptor (GPCR) pharmacogenomics Miles D Thompson , David interrogation of GPCR co-internalization Kilian Roßmann , Ramona Birke , Joshua Levitz , Ben Jones , Johannes
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
Parkinson’s Disease: A Mini-Review of Clinical Pharmacology. 2006 . (4)        Garcia-Borreguero, D. 2018 , 839 , 40–46. https://doi.org/10.1016/j.ejphar.2018.09.008 . (8)        Rinken, A.; Lavogina, D. D.; Hanada, K.; Pagano, R. E.; Miller, L. J. -J.; Kopanchuk, S.; Laasfeld, T.; Weinhart, M.; Schollmeyer, D.; Betschart, M.
- 📰 GPCR Weekly News
currents GPCR Binders, Drugs, and more LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine
- 📰 GPCR Weekly News, January 30 to February 5, 2023
Comparative evaluation of biased agonists Sarcosine1 , d-Alanine8 -Angiotensin (Ang) II (SD Ang II) and GPCRs in Oncology and Immunology LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
endosomes and other organelles. eLife. 2024 Nov 8; 13:RP97033. doi: 10.7554/eLife.97033.3 Â Maurel D,
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. Looking Ahead As we move into 2026, our focus remains simple: keep building with purpose — strengthening
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
Every R&D team is under the same pressure: deliver validated targets, clean pharmacology, and translatable busy scientists 💡 Influence the curriculum with your topic suggestions 🆕 Weekly new releases to stay ahead
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
is strategic, method-proven insight for discovery teams, pharmacologists refining core skills, and R&D
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
Hilger, D., et al., Structural insights into differences in G protein activation by family A and family
- Your GPCR Program Decisions Depend on Good Data Interpretation
startup environments Read Maria Majellaro's Full Recap ➤ Lab Leadership Without Ego: A Model for R&D
- How Collaboration Drives GPCR Discoveries
For Hodson, that moment came with a protein he’d been tracking for a decade: vitamin D binding protein
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
do: bring four decades of frontline discovery insight straight to discovery-phase scientists and R&D
- Dr. GPCR University registration is now open! Secure your spot now!
on Smooth operator(s): dialing up and down neurotransmitter responses by G-protein regulators András D
- 📰 GPCR Weekly News, June 24 to 30, 2024
Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D
- 📰 GPCR Weekly News, February 13 to 19, 2023
GPCR Activation and Signaling Statins inhibit protein kinase D (PKD) activation in intestinal cells and
- 📰 GPCR Weekly News, March 6 to 12, 2023
Structural and Molecular Insights into GPCR Function Endogenous l- to d-amino acid residue isomerization
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Wootten, D., et al., The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Devki D Sukhtankar and Pina M Cardarelli's research: Burixafor Hydrobromide (GPC-100) effects on hematopoietic
- VAMP2: a crucial player in the delivery of MOR to the synapse
Jurado, S., D. Goswami, Y. Zhang, A.J.M. Molina, T.C. Südhof, and R.C. Malenka. 2013.
- Unlocking the Future of Medicine: Advancements in GPCR Research
G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation Chiara D
- How System-Level GPCR Thinking Prevents Discovery Failures
Johannes Broichhagen Reliable imaging tools change how researchers see receptor behavior. Johannes Broichhagen explains how next-generation fluorescent probes—designed with precise synthetic
- 📰 GPCR Weekly News, May 29 to June 4, 2023
Scribble scrambles parathyroid hormone receptor interactions to regulate phosphate and vitamin D homeostasis
- 📰 GPCR Weekly News, October 30 to November 4, 2023
First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives R&D
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
from September 30th to October 6th, 2024 Industry News Nxera Pharma appoints experienced commercial R&D
- Regulators of G-protein signaling: essential players in GPCR signaling
Wang, D., The essential role of G protein-coupled receptor (GPCR) signaling in regulating T cell immunity
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth
- Overview of adhesion GPCRs self-activation
Araç, D., et al., A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis

















